Investor directory

Euphrates Vascular

Euphrates Vascular specializes in the development of medical devices aimed at treating vascular occlusions associated with vascular diseases. The company has created a Magnetically-Enhanced Diffusion system that utilizes patented magnet-based technology to enhance the delivery of iron-oxide MED MicroBeads and clot-busting medications. This innovative approach allows for a significantly faster transport of these treatments compared to traditional methods, thereby enabling healthcare providers to improve patient outcomes in conditions such as stroke. Euphrates Vascular was formed through the merger of Pulse Therapeutics and ICHOR Vascular, positioning it as a leader in advancing vascular treatment solutions.

Top Stages

Acquisition
https://euphratesvascular.com
https://crunchbase.com/organization/euphrates-vascular
https://facebook.com/pulsemedsystem
https://linkedin.com/company/euphrates-vascular
https://pitchbook.com/profiles/company/50839-21
https://twitter.com/pulsemedsystem

Catherine Matthes

CFO

1 past transactions

Euphrates Vascular

Acquisition in 2019
Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.